- Details
- Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic virus targeting cells with retinoblastoma pathway defects, common in cancer cells. This treatment, when instilled in the bladder, prompts immune cells to destroy cancer cells. Highlighted are several key trials: CORE-00...
|
- Details
- Tom Jayram hosts a panel of experts to discuss advancements in bladder cancer treatment, emphasizing personalized therapies, clinical trials, and the importance of a comprehensive approach. They highlight the role of nephron-sparing techniques and new tests in improving traditional diagnostic methods. Biographies: Tom Jayram, MD, Urology Associates P.C, Nashville, TN Daniel Saltzstein, MD, Urology...
|
- Details
- Ashish Kamat and Petros Grivas discuss recent advancements in metastatic bladder cancer treatments from ESMO Congress 2023. Key highlights include the CheckMate-901 and EV-302 trials. Dr. Grivas highlights the CheckMate-901 trial's success with the combination of gemcitabine, cisplatin, and nivolumab, which shows notable improvements in overall survival and progression-free survival with a managea...
|
- Details
- Ashish Kamat hosts Bente Jensen and Alex Filicevas to discuss key findings from a global survey on bladder cancer patient experiences and the supportive and complementary care needs of patients. This discussion is part of a four-part series in collaboration with UroToday and the World Bladder Cancer Patient Coalition. The World Bladder Cancer Patient Coalition serves as an international platform c...
|
- Details
- Ashish Kamat is joined by Lori Cirefice and Lydia Makaroff who discuss the findings of the Global World Bladder Cancer Patient Coalition Survey, focusing on the impact of bladder cancer on daily life and caregivers. The survey, which garnered nearly 1,200 responses from 45 countries, reveals significant financial and emotional strain on patients and their carers. Key findings include that 50% of p...
|
- Details
- Vedang Murthy discusses his study on the quality of life in bladder cancer patients undergoing either cystectomy (surgery) or bladder preservation (chemo-radiotherapy). The study aims to fill a gap in understanding how each treatment impacts patients' quality of life, especially since recent research suggests that both treatments offer similar clinical outcomes. Surprisingly, the study found no si...
|
- Details
- Ashish Kamat discusses the World Bladder Cancer Patient Coalition's Bladder Cancer Patient and Carer Experience Survey with Stephanie Demkiw and Lydia Makaroff. The survey reveals that awareness of bladder cancer symptoms is low, with over half of the respondents unaware of the signs before diagnosis. Dr. Demkiw highlights that women are often diagnosed later than men and discusses the importance...
|
- Details
- Ashish Kamat is joined by Pat Hensley and Lydia Makaroff, who share insights into patient experiences and treatment access. Drs. Hensley and Makaroff delve into the findings of the Global Bladder Cancer Patient and Care Experience survey, conducted by the World Bladder Cancer Patient Coalition. The survey, which garnered 1,198 respondents from diverse geographies, reveals that while 58% of patient...
|
- Details
- Zach Klaassen is joined by Karsten Zieger to talk about the results of an analysis from the Nordic registry evaluating the role of flexible blue light cystoscopy in the surveillance of non-muscle invasive bladder cancer. Dr. Zieger provides a comprehensive explanation of how blue light cystoscopy works. The method utilizes a photosensitizing agent, Hexvix in Europe or Cysview® in the U.S., that al...
|
- Details
- Leslie Ballas engages with Martin Swinton on his publication about bladder-sparing treatment options for clinically node-positive nonmetastatic bladder cancer. The study compares the efficacy of bladder-sparing treatment using radical dose radiotherapy to traditional radical cystectomy and finds no significant difference in overall survival rates. This supports bladder preservation as a viable alt...
|